PRADC1

Across TCGA pan-cancer cohorts, PRADC1 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of PRADC1’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where PRADC1 RNA is repressed in tumor relative to normal tissue. In most cancer types PRADC1 is over-expressed in tumor, although a few such as THCA and HNSC show the opposite, repressed pattern.

THCA, HNSC, and LIHC are the cancer types where PRADC1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRADC1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−1.305	<.001	9	view →
HNSC	Male	All	−0.672	<.001	9	view →
LIHC	Female	II,III,IV	+0.933	<.001	8	view →
KIRC	Male	II,III,IV	−0.627	<.001	7	view →
COAD	Male	All	−0.722	<.001	6	view →
KICH	All	All	−0.622	.001	3	view →
STAD	All	All	−0.364	.024	3	view →
READ	All	All	−0.799	.019	2	view →
UCEC	All	All	+0.552	.008	2	view →
PRAD	All	All	−0.300	.005	2	view →
BLCA	Female	IV	+0.830	.031	1	view →
CHOL	All	All	−0.525	.020	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

PRADC1–THCA

Open the THCA breakdown →